Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.
Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing - Y(90) ibritumomab tiuxetan and I(131) tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.
Davies
A J
AJ
Department of Medical Oncology, St Bartholomew's Hospital, London, UK. andrew.davies1@bartsandthelondon.nhs.uk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D012008:Recurrence
D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan; C119496:tositumomab I-131